Conserved serine residues in serotonin transporter contribute to high-affinity cocaine binding

Biochemical and Biophysical Research Communications

Volumn 343, Issue 4, 2006, Pages 1179-1185

  Gu, Howard H ^a   Wu, Xiaohong ^b   Han, Dawn D ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Molecular Staging Inc   (United States)

Author keywords

Bombyx mori; Cloning; Cocaine; Dopamine transporter; Inhibition; Mutagenesis; Serotonin transporter

Indexed keywords

COCAINE; SERINE; SEROTONIN TRANSPORTER;

ARTICLE; BINDING AFFINITY; CELL CULTURE; CONTROLLED STUDY; MOLECULAR CLONING; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SILKWORM;

AMINO ACID SEQUENCE; ANIMALS; BOMBYX; COCAINE; CONSERVED SEQUENCE; DROSOPHILA PROTEINS; HELA CELLS; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; SERINE; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; THREONINE;

BOMBYX MORI; DROSOPHILA MELANOGASTER; MAMMALIA;

EID: 33646065964     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.03.096     Document Type: Article

References (36)

1. Iversen L.L. Role of transmitter uptake mechanisms in synaptic neurotransmission. Br. J. Pharmacol. 41 (1971) 571-591
2. Kanner B.I., and Schuldiner S. Mechanism of transport and storage of neurotransmitters. CRC Critical Rev. Biochem. 22 (1987) 1-38
3. Amara S.G., and Arriza J.L. Neurotransmitter transporters: Three distinct gene families. Curr. Opin. Neurobiol. 3 (1993) 337-344
4. Rudnick G., and Clark J. From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim. Biophys. Acta 1144 (1993) 249-263
5. Ritz M.C., Lamb R.J., Goldberg S.R., and Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237 (1987) 1219-1223
6. Giros B., and Caron M.G. Molecular characterization of the dopamine transporter. Trends Pharmacol. Sci. 14 (1993) 43-49
7. Gu H., Wall S.C., and Rudnick G. Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J. Biol. Chem. 269 (1994) 7124-7130
8. Han D.D., and Gu H.H. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol. 6 (2006) 6
9. Koe B.K. Preclinical pharmacology of sertraline: A potent and specific inhibitor of serotonin reuptake. J. Clin. Psychiatry 51 Suppl B (1990) 13-17
10. Goodnick P.J. Pharmacokinetics of second generation antidepressants: bupropion. Psychopharmacol. Bull. 27 (1991) 513-519
11. Barr L.C., Goodman W.K., Price L.H., McDougle C.J., and Charney D.S. The serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies. J. Clin. Psychiatry 53 Suppl (1992) 17-28
12. Boyer W.F., and Feighner J.P. An overview of paroxetine. J. Clin. Psychiatry 53 Suppl (1992) 3-6
13. Ascher J.A., Cole J.O., Colin J.N., Feighner J.P., Ferris R.M., Fibiger H.C., Golden R.N., Martin P., Potter W.Z., Richelson E., et al. Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry 56 (1995) 395-401
14. Klein R.G. The role of methylphenidate in psychiatry. Arch. Gen. Psychiatry 52 (1995) 429-433
15. Seeman P., and Madras B.K. Anti-hyperactivity medication: methylphenidate and amphetamine [in process citation]. Mol. Psychiatry 3 (1998) 386-396
16. Smith B.H., Pelham W.E., Gnagy E., and Yudell R.S. Equivalent effects of stimulant treatment for attention-deficit hyperactivity disorder during childhood and adolescence. J. Am. Acad. Child Adolesc. Psychiatry 37 (1998) 314-321
17. Giros B., Wang Y.M., Suter S., McLeskey S.B., Pifl C., and Caron M.G. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J. Biol. Chem. 269 (1994) 15985-15988
18. Kitayama S., Shimada S., Xu H., Markham L., Donovan D.M., and Uhl G.R. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc. Natl. Acad. Sci. USA 89 (1992) 7782-7785
19. Buck K.J., and Amara S.G. Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants. Mol. Pharmacol. 48 (1995) 1030-1037
20. Lin Z., Itokawa M., and Uhl G.R. Dopamine transporter proline mutations influence dopamine uptake, cocaine analog recognition, and expression. FASEB J. 14 (2000) 715-728
21. Lin Z., Wang W., Kopajtic T., Revay R.S., and Uhl G.R. Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition. Mol. Pharmacol. 56 (1999) 434-447
22. Chen N., Vaughan R.A., and Reith M.E. The role of conserved tryptophan and acidic residues in the human dopamine transporter as characterized by site-directed mutagenesis. J. Neurochem. 77 (2001) 1116-1127
23. Fong T.M., Yu H., and Strader C.D. Molecular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96,345 and RP67580. J. Biol. Chem. 267 (1992) 25668-25671
24. Oksenberg D., Marsters S.A., O'Dowd B.F., Jin H., Havlik S., Peroutka S.J., and Ashkenazi A. A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature 360 (1992) 161-163
25. Hall J.M., Caulfield M.P., Watson S.P., and Guard S. Receptor subtypes or species homologues: relevance to drug discovery. Trends Pharmacol. Sci. 14 (1993) 376-383
26. Barker E.L., Perlman M.A., Adkins E.M., Houlihan W.J., Pristupa Z.B., Niznik H.B., and Blakely R.D. High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis. An aromatic residue in transmembrane domain I dictates species-selective recognition of citalopram and mazindol. J. Biol. Chem. 273 (1998) 19459-19468
27. Lee S.H., Chang M.Y., Lee K.H., Park B.S., Lee Y.S., and Chin H.R. Importance of valine at position 152 for the substrate transport and 2β-carbomethoxy-3β-(4-fluorophenyl)tropane binding of dopamine transporter. Mol. Pharmacol. 57 (2000) 883-889
28. Mortensen O.V., Kristensen A.S., and Wiborg O. Species-scanning mutagenesis of the serotonin transporter reveals residues essential in selective, high-affinity recognition of antidepressants. J. Neurochem. 79 (2001) 237-247
29. Wu X., and Gu H.H. Cocaine affinity decreased by mutations of aromatic residue phenylalanine 105 in the transmembrane domain two of dopamine transporter. Mol. Pharmacol. 63 (2003) 653-658
30. Henry L.K., Field J.R., Adkins E.M., Parnas M.L., Vaughan R.A., Zou M.F., Newman A.H., and Blakely R.D. Tyr-95 and ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. J. Biol. Chem. 281 (2006) 2012-2023
31. Chen J.G., Sachpatzidis A., and Rudnick G. The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding. J. Biol. Chem. 272 (1997) 28321-28327
32. Chen R., Wu X., Wei H., Han D.D., and Gu H.H. Molecular cloning and functional characterization of the dopamine transporter from Eloria noyesi, a caterpillar pest of cocaine-rich coca plants. Gene 366 (2006) 152-160
33. Chen R., Han D.D., and Gu H.H. A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate. J. Neurochem. 94 (2005) 352-359
34. Blakely R.D., Clark J.A., Rudnick G., and Amara S.G. Vaccinia-T7 RNA polymerase expression system: evaluation for the expression cloning of plasma membrane transporters. Anal. Biochem. 194 (1991) 302-308
35. Wu X.H., and Gu H.H. Molecular cloning of the mouse dopamine transporter and pharmacological comparison with the human homologue. Gene 233 (1999) 163-170
36. - dependent neurotransmitter transporters. Nature 437 (2005) 215-223